A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03105128 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

931

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: placebo for risankizumab
DRUG: risankizumab IV
DRUG: risankizumab SC

Sponsor

AbbVie